Abstracts tagged "Osteoarthritis"

Abstract Number: 0821 • ACR Convergence 2023
Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study
Philip Conaghan¹, Nathaniel Katz², david Hunter³, Marc Hochberg⁴, Ali Guermazi⁵, Kenneth Somberg⁶, Julia Clive⁶, Mary Johnson⁶ and Niti Goel⁷, ¹University of Leeds, Leeds, United Kingdom, ²Tufts University and Ein Sof Innovation, Boston, MA, ³Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ⁴University of Maryland School of Medicine, Baltimore, MD, ⁵Boston University, Boston, MA, ⁶TrialSpark, New York, NY, ⁷TrialSpark, Duke University, Durham, NC
Background/Purpose: People with knee OA (KOA) desire therapies which delay or reverse disease progression supporting the need for disease-modifying OA drugs (DMOADs). Sprifermin, truncated recombinant…
Abstract Number: 0874 • ACR Convergence 2023
RNA-Binding Proteins That Are Highly Expressed and Enriched in Healthy Cartilage but Suppressed in Osteoarthritis
Hannah Swahn, Merissa Olmer and Martin K Lotz, Scripps Research Institute, La Jolla, CA
Background/Purpose: RNA-binding proteins (RBPs) have diverse and essential biological functions, but their role in cartilage health and disease is largely unknown. The objectives of this…
Abstract Number: 1184 • ACR Convergence 2023
A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker
Deepak Kumar¹, Lukas Adamowicz², Benjamin Senderling¹, Mary Gheller¹, Michael LaValley³, Kathryn Bacon¹, Pirinka Georgiev², Charmaine Demanuele², Paul Wacnik² and Tuhina Neogi⁴, ¹Boston University, Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this study in people with knee osteoarthritis (OA) were to (a) examine the agreement between measures of gait and chair stand…
Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Jost Klawitter¹, Andrew Clauw¹, Jennifer Seifert¹, Jelena Klawitter¹, Bridget Tompson¹, Cristina Sempio¹, Uwe Christians¹ and Larry Moreland², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO

Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…
Abstract Number: 1865 • ACR Convergence 2023
Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative
Daniel Chan Chun Kong¹, Philip Conaghan² and Mark Campbell³, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Leeds, Leeds, United Kingdom, ³Elisabeth Bruyere Hospital, Ottawa, ON, Canada
Background/Purpose: Knee flexion contracture (FC) is associated with worse clinical outcomes in those with knee OA. Cross sectional data demonstrated that knee FC was associated…
Abstract Number: 1987 • ACR Convergence 2023
Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis
Philip Conaghan¹, Felix Eckstein², Wolfgang Wirth³, Marc Hochberg⁴, Ali Guermazi⁵, Luping Zhao⁶ and Niti Goel⁷, ¹University of Leeds, Leeds, United Kingdom, ²Paracelsus Medical University, Institute of Anatomy & Ludwig Boltzmann Institute, and Chondrometrics GmbH, Salzburg, Austria, ³Paracelsus Medical University, Institute of Anatomy & Ludwig Boltzmann Institute, and Chondrometrics GmbH, Freilassing, Germany, ⁴University of Maryland School of Medicine, Baltimore, MD, ⁵Boston University, Boston, MA, ⁶TrialSpark, New York, NY, ⁷TrialSpark, Duke University, Durham, NC
Background/Purpose: Sprifermin is an investigational intra-articular (IA) recombinant human truncated fibroblast growth factor-18 (rhFGF-18) therapy evaluated to date in three knee osteoarthritis (KOA) trials (NCT00911469…
Abstract Number: 2472 • ACR Convergence 2023
Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
ting Jiang¹, Qianlin Weng¹, Jiatian Li², Yuqing Zhang³, Weiya Zhang⁴, Michael Doherty⁴, Tuo Yang⁵, Zidan Yang⁶, Ke Liu¹, Qiu Chen¹, Jie Wei⁷, Guanghua Lei² and Chao Zeng², ¹Xiangya Hospital, Central South University, Changsha, China, ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Academic Rheumatology, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham, United Kingdom, ⁵Department of Health Management Center, Xiangya Hospital, Central South University, Changsha, China, ⁶Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁷Health Management Center, Xiangya Hospital Central South University, Changsha, China
Background/Purpose: Synovitis is a modifiable pathological lesion of hand osteoarthritis (HOA). Although synovitis has been related to the prevalence and symptoms of HOA, it remains…
Abstract Number: 0317 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Martijn Gerritsen², Jos W.R. Twisk¹, Martin van der Esch², Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
Abstract Number: 0822 • ACR Convergence 2023
From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes
Monica Hannani¹, Zofia Lisowska-Petersen², Morten Karsdal², Cecilie Bager², Anne-Christine Bay-Jensen² and Christian Thudium², ¹University of Copenhagen, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) is a diverse and multifaceted condition. Despite its widespread incidence, the core mechanisms of the disease remain elusive, and therapeutic interventions are…
Abstract Number: 0875 • ACR Convergence 2023
INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
Jung Gyu Park¹, Yurim Lee¹, Joonghoon Park² and myungjin Kim³, ¹Innovo Therapeutics Inc., Daejeon, South Korea, ²Institute of Green Bio Science and Technology, Seoul National University, Pyeongchang, South Korea, ³HLB bioStep Co. Ltd, Incheon, South Korea
Background/Purpose: Osteoarthritis poses a substantial medical challenge, as the available treatments primarily target symptom relief and fail to effectively halt the progressive cartilage deterioration that…
Abstract Number: 1185 • ACR Convergence 2023
Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients
Tine Vanhaverbeke¹, Dirk Elewaut² and Ruth Wittoek¹, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: In osteoporotic patients, discontinuation of denosumab is associated with a rapid increase in bone turnover and bone loss. Denosumab was recently proven to have…
Abstract Number: 1581 • ACR Convergence 2023
Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes
Gabby Dyson¹, Montana Barrett², Meeshal Khan³, Cindy Miranda¹, Nicholas Hanebutt¹, Christopher Dunn³ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Guthrie, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: MRL/MpJ mice are protected from developing post-traumatic osteoarthritis (OA). We have previously shown transplantation prior to OA induction prevents OA development. We now extend…
Abstract Number: 1874 • ACR Convergence 2023
Cartilage Thickness Measures Are More Responsive Than Cartilage Area Loss Measures: A Comparison of Quantitative and Semi-quantitative Cartilage Assessments from the Osteoarthritis Initiative
Aaron Ray¹, Alan Brett², Bright Dube³, Michael Bowes⁴ and Philip Conaghan³, ¹York and Scarborough Teaching Hospitals: NHS Foundation Trust, York, United Kingdom, ²Stryker, Austin, TX, ³University of Leeds, Leeds, United Kingdom, ⁴Imorphics Ltd, Manchester, United Kingdom
Background/Purpose: Cartilage loss in 1-2 year osteoarthritis clinical trials is often small, but a critical outcome measure. The aim of this study was to compare…
Abstract Number: 1988 • ACR Convergence 2023
Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis
Andrew Spitzer¹, Helena Rodbard², Sheikh Usman Iqbal³, Masato Nakazawa³, Mary DiGiorgi³ and Roy Winston³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Endocrine and Metabolic Consultants, Rockville, MD, ³Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Intraarticular (IA) corticosteroids are generally considered safe and effective to treat osteoarthritis of the knee (OAK) but may cause hyperglycemia that may last for…
Abstract Number: 2498 • ACR Convergence 2023
Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?
Sydney Liles¹, Daniel White², Thomas Bye² and Jason Jakiela², ¹University of Delaware, Elkton, MD, ²University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading global cause of pain and disability, with no current cure. Knee pain is the most common symptom and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].